Prevalence of radiotherapy, chemotherapy and access to supportive care in cancer in Brazil, China, France, Russia and the USA.


Journal

European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979

Informations de publication

Date de publication:
Nov 2022
Historique:
revised: 09 05 2022
received: 08 01 2022
accepted: 06 06 2022
pubmed: 17 6 2022
medline: 30 11 2022
entrez: 16 6 2022
Statut: ppublish

Résumé

The objective of this study is to assess the prevalence of treatment with radiotherapy and/or chemotherapy in the general adult population of five countries (Brazil, China, France, Russia and the USA) and to evaluate the use of different Supportive Care in Cancer (SCC) services. A total of 11,100 individuals representing the general population over 18 years of age were recruited from the five countries via a rigorous quota sampling method. There are between 4.1% and 8.78% of respondents reported having undergone medical cancer treatment. Among these subpopulations, the use of at least one SCC was reported by 63% to 86% of respondents. The most commonly used SCC was psychological counselling in France, dietary counselling in Brazil and China, participating in a focus group in the USA and using alternative medicine in Russia. Alternative medicines were chosen by 50% to 61% of patients in every country. This study provides information on the prevalence of patients treated by chemotherapy and/or radiotherapy in representative populations from five countries. Among them, SCC was widely used. However, these uses varied both in proportion and choice, given the cultural differences in patients' and families' health beliefs and values, differences among organisations, in available resources and in ethics and policies among countries.

Identifiants

pubmed: 35708175
doi: 10.1111/ecc.13636
pmc: PMC9787726
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e13636

Subventions

Organisme : Laboratoire La Roche Posay

Informations de copyright

© 2022 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd.

Références

Psychooncology. 2010 Jun;19(6):606-16
pubmed: 19557823
Prev Med. 2016 Nov;92:110-117
pubmed: 26902875
Public Health. 2015 Jun;129(6):611-20
pubmed: 26025176
JAMA Oncol. 2018 Oct 1;4(10):1375-1381
pubmed: 30027204
Cochrane Database Syst Rev. 2014 Nov 26;(11):CD010470
pubmed: 25425011
Support Care Cancer. 2009 Aug;17(8):1117-28
pubmed: 19319577
Br J Dermatol. 2019 Jun;180(6):1549-1550
pubmed: 30500070
Acta Derm Venereol. 2020 Nov 18;100(18):adv00327
pubmed: 33196099
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922780
Open Med. 2014 Apr 15;8(2):e54-66
pubmed: 25009685
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13636
pubmed: 35708175
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419854134
pubmed: 31170844
J Clin Oncol. 2012 Feb 1;30(4):394-400
pubmed: 22203758
Breast. 2013 Oct;22(5):593-605
pubmed: 24001709
J Clin Oncol. 2012 Apr 20;30(12):1310-5
pubmed: 22430269
Support Care Cancer. 2012 Feb;20(2):207-19
pubmed: 22089430
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Oncologist. 2006 Jul-Aug;11(7):742-52
pubmed: 16880233
Support Care Cancer. 2008 Mar;16(3):235-40
pubmed: 18196291
PLoS One. 2013 May 31;8(5):e65099
pubmed: 23741467
Support Care Cancer. 2005 Aug;13(8):607-27
pubmed: 16041463
Support Care Cancer. 2016 Nov;24(11):4479-81
pubmed: 27543163
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e436-e439
pubmed: 33368663
Health Expect. 2002 Dec;5(4):289-301
pubmed: 12460218
Bull Cancer. 2018 Sep;105(9):763-770
pubmed: 30097280
Crit Rev Oncol Hematol. 2018 Nov;131:90-95
pubmed: 30293711
J Support Oncol. 2013 Sep;11(3):105-13
pubmed: 24400390
Integr Med Insights. 2008;3:1-11
pubmed: 21614154

Auteurs

Guillaume Buiret (G)

Plateforme de soins oncologiques de support, CH Valence, Valence, France.

Véronique Delvigne (V)

Direction Scientifique, Laboratoire La Roche Posay, Levallois Perret, France.

Guénaëlle le Dantec (G)

Direction Scientifique, Laboratoire La Roche Posay, Levallois Perret, France.

Pascale Guyonnet-Debersac (P)

Direction Scientifique, Laboratoire La Roche Posay, Levallois Perret, France.

Charles Taïeb (C)

Hôpital Necker Enfants-Malades, Fimarad, Paris, France.
Société Française Sciences Humaines de la Peau, Maison de la Dermatologie, Paris, France.
European Market Maintenance Assessment, EMMA, Vincennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH